Health Care & Life Sciences » Pharmaceuticals | Concert Pharmaceuticals Inc.

Concert Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
6,056.00
31,699.00
24,174.00
50,720.00
95,639.00
56,024
Depreciation, Depletion & Amortization
1,346.00
1,052.00
785.00
893.00
1,008.00
1,247
Other Funds
2,024.00
-
130.00
-
-
2,778
Funds from Operations
3,710.00
28,235.00
28,454.00
44,569.00
106,557.00
51,999
Changes in Working Capital
16,728.00
1,831.00
5,393.00
774.00
3,630.00
3,970
Net Operating Cash Flow
13,018.00
30,066.00
23,061.00
45,343.00
102,927.00
48,029
Capital Expenditures
363.00
804.00
868.00
770.00
947.00
Purchase/Sale of Investments
3,274.00
43,648.00
15,437.00
6,443.00
120,360.00
Net Investing Cash Flow
3,637.00
44,452.00
14,569.00
7,213.00
121,307.00
Issuance/Reduction of Debt, Net
5,241.00
8,182.00
7,175.00
-
1,086.00
Net Financing Cash Flow
7,233.00
77,970.00
41,484.00
601.00
5,490.00
Net Change in Cash
2,148.00
3,452.00
79,114.00
51,955.00
12,890.00
Free Cash Flow
12,655.00
30,870.00
22,193.00
46,113.00
101,980.00
Change in Capital Stock
32.00
86,152.00
48,529.00
601.00
6,576.00

About Concert Pharmaceuticals

View Profile
Address
99 Hayden Avenue
Lexington Massachusetts 02421
United States
Employees -
Website http://www.concertpharma.com
Updated 07/08/2019
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.